Oncocyte CORP 8-K filings

Insight Molecular Diagnostics reports progress on its GraftAssureDx FDA submission and positive developments in Medicare reimbursement, alongside Q2 2026 financial results.

Insight Molecular Diagnostics Inc. announced its Q1 2026 financial results, highlighting progress in commercializing its GraftAssureDx transplant rejection monitoring test and advancements in clinical trial engagement.

Insight Molecular Diagnostics Inc. amends a prior 8-K filing to correctly disclose a Specimen Collection Agreement with Quest Diagnostics for its GraftAssureCoreTM test.

Insight Molecular Diagnostics Inc. filed an 8-K to correct a clerical error in the Third Amended and Restated Bylaws previously incorporated into its 2025 Annual Report.

Insight Molecular Diagnostics Inc. submitted its GraftAssureDx kidney transplant rejection test for FDA review and reported Q4 and full-year 2025 financial results.

Insight Molecular Diagnostics Inc. has partnered with Quest Diagnostics for specimen collection services related to its GraftAssureCore test.

Insight Molecular Diagnostics Inc. announced a $26.0 million registered direct offering to fund R&D, including expansion of its GraftAssure product line.

Insight Molecular Diagnostics Inc. announced its intent to use an investor presentation at upcoming meetings with investors and analysts.

Insight Molecular Diagnostics Inc. announced its third quarter 2025 financial results and significant progress towards FDA submission for its GraftAssureDx molecular diagnostic test kit.

Insight Molecular Diagnostics Inc. announced the grant of stock options to key executives and an amendment to its Chief Science Officer's employment agreement, removing the fixed term expiration.

Insight Molecular Diagnostics Inc. announced significant base salary increases for its President and CEO, Joshua Riggs, and CFO, Andrea James, effective September 15, 2025.

Insight Molecular Diagnostics reports Q2 2025 results, reiterates FDA submission timeline for GraftAssureDx by year-end, and highlights progress in transplant and oncology pipelines.

Insight Molecular Diagnostics Inc. announced that its shareholders approved all four proposals at the 2025 Annual Meeting, including the election of directors, ratification of its accounting firm, executive compensation, and an increase in shares authorized under its equity incentive plan.

Oncocyte Corporation has officially changed its name to Insight Molecular Diagnostics Inc. (iMDx) and its Nasdaq ticker to IMDX, signaling a strategic pivot towards molecular diagnostics in transplant medicine and a relocation of its principal executive office to Nashville, Tennessee.

Oncocyte Corp. announces Q1 2025 results, highlighting progress in clinical trials and exceeding expectations with $2.1 million in pharma services revenue.

Oncocyte Corporation terminates its relationship with Marcum LLP and engages CBIZ CPAs as its independent registered public accounting firm for the fiscal year ending December 31, 2025.

Oncocyte Corp. announces its Q4 2024 and full-year results, highlighting progress in transplant diagnostics and setting the stage for key milestones in 2025.

Oncocyte Corporation's Board of Directors approved salary increases, bonuses, and RSU grants for key executives, and promoted James Liu to Vice President Accounting, Controller, Treasurer and Principal Accounting Officer.

Oncocyte Corp. announces a $29.1 million equity offering, led by strategic partner Bio-Rad, to fund its transplant assay through FDA clearance and commercial launch.

Oncocyte Corporation has amended its lease agreement, terminating extension options and securing a phased reduction of a $1.7 million letter of credit starting July 2025.

Oncocyte is making significant strides in commercializing its transplant testing technology, securing new research customers and advancing its clinical kitted test development, while also raising $10.2 million through a private placement.

Oncocyte Corporation's stockholders approved an amendment and restatement of the company's 2018 Equity Incentive Plan, increasing the number of shares available for issuance and modifying certain plan provisions.

Oncocyte Corporation has successfully raised $10.2 million through a private placement to advance its organ transplant testing and general corporate activities.

Oncocyte Corporation has entered into a sales agreement with Needham & Company, LLC to potentially sell up to $7.5 million of its common stock through an at-the-market offering.

Oncocyte reports a successful beta launch of its GraftAssure transplant assay and second quarter 2024 financial results, emphasizing a land and expand strategy in the transplant market.

Oncocyte Corporation has regained compliance with Nasdaq listing rules after a temporary non-compliance due to the passing of a director and subsequent appointment of a new independent director.

Oncocyte Corporation held its 2024 Annual Meeting of Shareholders, electing four directors, ratifying its accounting firm, and approving executive compensation on an advisory basis.

Oncocyte Corporation has appointed Andrea James as its new Chief Financial Officer, effective June 17, 2024.

Oncocyte Corporation's Board of Directors has approved salary increases for its CEO, CFO, and Chief Science Officer, effective May 20, 2024.

Oncocyte Corporation has entered into an employment agreement with Ekkehard Schtz, M.D., Ph.D., appointing him as Chief Science Officer, effective May 20, 2024.